Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology Gets $6.5M Investment from Abraxis

NEW YORK (GenomeWeb News) – Expression Pathology, a Gaithersburg, Md.-based developer of technology for analyzing protein biomarkers in tissue, has received $6.5 million in financing from biopharmaceutical firm Abraxis BioScience.

Expression Pathology said that the funds would be used to apply its Liquid Tissue proteomics technology to the development of personalized medicine assays for measuring protein biomarkers of drug response and disease prognosis to specific patient treatment decisions.

"We believe the ability of our technology to interrogate archived tissue collections to discover and validate protein biomarkers that relate to disease progression, drug response and toxicity, and to measure those biomarkers accurately in standard tissue from clinical trials and medical care, will translate into a tremendously valuable asset," Casey Eitner, president and CEO of Expression Pathology, said in a statement.

Expression Pathology did not disclose how much of an equity stake Abraxis holds in the firm.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.